Mirtazapina Tarbis (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Tarbis, is a noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral administration. It is indicated for the management of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier, providing reliable bulk shipments to hospitals, pharmacies, and clinics across Europe and other global markets while adhering to stringent quality and regulatory standards through validated manufacturing processes.

Mirtazapine acts on the central noradrenergic and serotonergic pathways to treat depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adults. - Depressive episodes in bipolar I disorder (adjunct): may alleviate depressive phases when used with mood stabilizers. - Depression with prominent insomnia: helps improve sleep quality while treating depressive symptoms.

Mirtazapine may cause a variety of adverse reactions, ranging from mild and frequently observed effects to rare but potentially serious conditions that require immediate medical attention.

Common Side Effects: - Sedation or drowsiness: feeling unusually sleepy, especially after the first dose. - Increased appetite and weight gain: heightened hunger that may lead to gradual weight increase. - Dry mouth: reduced salivation causing discomfort. - Constipation: infrequent bowel movements or hard stools.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia: dangerously low white‑blood‑cell count requiring urgent care. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions with blistering and detachment. - Suicidal thoughts or worsening depression: emergence of suicidal ideation, particularly early in therapy.

When prescribing mirtazapine, clinicians should consider several precautionary measures to ensure safe use.

- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Elderly patients: increased sensitivity to sedation and risk of falls. - History of bipolar disorder: may trigger manic or hypomanic episodes. - Concomitant CNS depressants: potential additive sedation, monitor closely. - Liver impairment: dose adjustment may be necessary due to altered metabolism. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol): additive serotonin effects. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Alcohol or CNS depressants: enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect. - Anticholinergic drugs: combined dry mouth and constipation. - Warfarin: possible alteration of INR, requiring monitoring.